Daily Dose: Healthy Lifestyle & Risk of CVD Among Postmenopausal Women With Normal BMI
Your daily dose of clinical news you may have missed.
For Unknown Causes of Kidney Disease, Genetic Testing Holds Promise
A recent American Kidney Fund survey of 300 primary care and specialty clinicians found ~15% of their patients had kidney disease of unknown origin.
Home Blood Pressure Monitoring among Older US Adults
Among adults aged 50 to 80 years with a BP-related condition, less than half say they regularly monitor BP at home; one-third are "not very concerned" about their BP.
Empagliflozin and Empagliflozin/Metformin Win FDA Approval for Pediatric Type 2 Diabetes
The 2 SGLT-2 inhibitor-based medications are the first in the class to be approved for pediatric T2D and provide a much needed additional oral treatment option for the population.
Daily Dose: Cardiovascular Safety of Testosterone-Replacement Therapy in Men with Hypogonadism
Healthy Lifestyle Linked to Primary CVD Prevention in Postmenopausal Women with Normal BMI
Higher scores on a healthy lifestyle index were associated with significantly reduced risk of incident CVD among women aged 50-79 years with BMI between 18.5 and 25.0.
USPSTF: Screen Adults for Depression, Anxiety, Suicide Risk in Primary Care
Primary care clinicians should screen all adults for the 3 mental health conditions to ensure timely referral for appropriate treatment.
FDA Approves Low-Dose Colchicine as First Anti-inflammatory Therapy to Reduce Cardiovascular Events
Colchicine 0.5 mg is associated with reduction in a wide range of CV events in patients already on statin therapy, supporting the long-held "anti-inflammatory" hypothesis.
Testosterone Replacement Does Not Increase Risk for CV Events in Men with Hypogonadism, New Study Finds
ENDO 2023. In older men with hypogonadism and CVD, there was no difference in incident CVD between those taking testosterone and those taking placebo.
Obesity and Type 2 Diabetes: Experts Analyze the Role of Insulin Resistance
Listen to 2 obesity experts discuss and analyze the role of insulin resistance in type 2 diabetes and obesity.
Daily Dose: PCOS Associated with Higher Mortality Risk
Polycystic Ovary Syndrome Associated with Higher Mortality Risk, According to New Research
ENDO 2023. Women with PCOS face an increased risk of mortality, particularly death due to cardiovascular disease and diabetes, compared with those without PCOS.
Friday's 5 Quotes for Primary Care 6-19-2023
Ozempic impact on patients, clinicians; bempedoic acid comparable to statins; hypertension risk upped with oral estrogen HT; and 2 more quotes of note.
Bempedoic Acid Found Comparable to Statins for Lowering LDL-C, Reducing Major CV Event Risk
ENDO 2023: Treatment with bempedoic acid was found comparable to statin therapy in an analysis of the CLEAR Outcomes trial based on CTT Collaboration methodology.
Early Time-restricted Feeding Regimen Improves Glycemic Variability, Time in Range in Patients with Prediabetes, Obesity
ENDO 2023. The pattern of intermittent fasting improved glycemic measures in a weight-independent fashion after just 7 days, according to the study abstract.
FDA Advisory Committee Unanimous: COVID-19 Vaccines Should be Monovalent, Contain XBB Strain
The FDA's VRBPAC members were unanimous in their recommendation that the 2023-24 COVID vaccines reflect the dominant strain in circulation, XBB.
AMA Urges Clinicians to De-emphasize Use of BMI to Gauge Health, Obesity
Acknowledging the historical harm caused by sole reliance on the measure for decisions in clinical practice, the AMA urges clinicians to incorporate other valid measures.
Daily Dose: Finerenone Reduces CKD-associated CV Risk in Patients with T2D
Monovalent Vaccine Against SARS-CoV-2 XBB Lineage Leads June 15 VRBPAC Meeting Agenda
The FDA advisory committee will review all current surveillance data and recommend which strain/s to include in updated COVID-19 vaccines for the 2023-2024 vaccination campaign.
Finerenone Reduces CKD-associated Composite Cardiovascular Risk in a New Subanalysis of FIDELITY Trial
Finerenone was associated with a decrease in composite CV risk in patients with CKD, T2D, eGFR of ≥25, and moderately to severely increased albuminuria.
